Menu
Breakthrough protein technologies
for each phase of the drug development process
Inoviem is the only bioanalytical CRO to use label-free technologies under physiological conditions and in human tissue. NPOT® and PIMS® have proved to bring significant advantages to target identification and in confirming target engagement with compounds.
NPOT® is a biophysical platform that maps how drugs interact with proteins in their native, unaltered state. By analysing tissues, cell lines, or patient biopsies directly, NPOT® identifies drug targets, interaction networks, and biomarkers; without disrupting the natural biological environment. Compatible with small molecules, antibodies, peptides, and large compounds, NPOT® accelerates drug discovery by revealing how therapies truly work in disease contexts.
PIMS® is a patented, label-free biophysical and analytical technology designed to study molecular interactions and predict therapeutic responses in biomedical research.
By leveraging near-infrared (NIR) spectroscopy, PIMS® detects subtle nanoscale modification when proteins and other biomolecules interact with drugs or other exogenous molecules. This unique approach generates dynamic “fingerprints” of a biological sample’s macromolecular structure and signalling activity, offering powerful insights into tissue response and personalized treatment outcomes.
LIPS is an innovative, label-free method designed to measure drug-target interactions with high accuracy in native environments, including cultured cells and patient tissues. By leveraging the natural charge and behavioural changes in proteins upon drug binding, LIPS separates proteins into aggregated (pellet) and soluble (supernatant) phases using pH-variable plates and hydrophobic conditions. This allows precise quantification of drug-induced effects without artificial markers.
Inoviem has developed a sensitive and accurate proteomic methodology for the proteomic profiling of human individuals in the context of translational evaluation of biomarkers and clinical development of new drug candidates. The methodology works with both human frozen whole blood and any other matrixes including plasma/sera, urine, sputum etc.
The workflow of MS-based proteomics experiments includes the following steps: experimental design, sampling, tissue/cell preparation, protein extraction, separation, MS analysis, protein identification, statistical analysis of data, validation of identification, quantification, and data analysis.
